Drugs / Clesrovimab
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Enflonsia | — | 2026-04-15 | europa.eu ↗ |
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03524118 | Sep 2018 → Sep 2022 | respiratory syncytial virus infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04086472 | Oct 2019 → Mar 2020 | respiratory syncytial virus infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04767373 | Apr 2021 → Jul 2024 | respiratory syncytial virus infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04938830 | Nov 2021 → Apr 2025 | respiratory syncytial virus infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clesrovimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04938830 ↗ |
| Known as | MK-1654 | “MK-1654” NCT04086472 ↗ |
| Action | Inhibit | “Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab” PMID 39601265 ↗ Mar 2025 |
| Modality | Monoclonal antibody | “Clesrovimab is an investigational monoclonal antibody” PMID 39601265 ↗ Mar 2025 |
| Route | Intramuscular | “Single ascending doses of clesrovimab will be administered via IM injection.” NCT03524118 ↗ |